- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Sequential molecularly targeted drug therapy including axitinib for a patient with end‐stage renal failure and metastatic renal cell carcinoma
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>A 62‐year‐old male patient with end‐stage renal disease and metastatic renal cell carcinoma (<jats:styled-content style="fixed-case">RCC</jats:styled-content>) was referred to our hospital. Sequential targeted therapy consisting of sorafenib, sunitinib, and everolimus was administered, but the patient's disease gradually progressed. Axitinib was subsequently administered at a decreased dose of 6 mg/day for 2 weeks, after which the dose was escalated to 10 mg/day. Axitinib therapy was maintained for a total of 6 months without severe adverse effects. Sequential molecularly targeted drug therapy including axitinib, with careful monitoring, is one possible treatment option for patients with metastatic <jats:styled-content style="fixed-case">RCC</jats:styled-content> with renal impairment.</jats:p>
Journal
-
- Hemodialysis International
-
Hemodialysis International 20 2015-08-25
Wiley